<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To develop an effective and safe therapeutic policy for Sandimmun-<z:chebi fb="0" ids="4031">Neoral</z:chebi> in order to prevent joint destruction, invalidation, achieve higher life quality in patients with systemic <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> (SJRA) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: The trial included 26 patients with SJRA aged 4-15 years </plain></SENT>
<SENT sid="2" pm="."><plain>12 of them had early SJRA, 14--late SJRA </plain></SENT>
<SENT sid="3" pm="."><plain>13 patients received <z:chebi fb="0" ids="4031">Neoral</z:chebi> for one year and the other 13 for 2-3.5 years </plain></SENT>
<SENT sid="4" pm="."><plain>Markers of aggressive SJRA course in the debut were registered in <z:hpo ids='HP_0000001'>all</z:hpo> the patients </plain></SENT>
<SENT sid="5" pm="."><plain>Previous treatment incorporated nonsteroid <z:chebi fb="3" ids="35472">antiinflammatory drugs</z:chebi>, intraarticular <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (<z:hpo ids='HP_0000001'>all</z:hpo> the patients), <z:chebi fb="2" ids="8378">prednisolone</z:chebi> (19 patients), <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (3 patients) </plain></SENT>
<SENT sid="6" pm="."><plain>Before <z:chebi fb="0" ids="4031">Neoral</z:chebi> treatment 80% of the patients had structural alterations in the joints, signs of invalidation, low quality of life </plain></SENT>
<SENT sid="7" pm="."><plain>SJRA activity was defined as the 3d degree </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients suffered from <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000998'>hypertrichosis</z:hpo>, steroid <z:e sem="disease" ids="C0037933" disease_type="Disease or Syndrome" abbrv="">spondylopathy</z:e>, nanism </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: <z:chebi fb="0" ids="4031">Neoral</z:chebi> recovered joint motility in 30% of patients, 60% were capable for self-service </plain></SENT>
<SENT sid="10" pm="."><plain>Quality of life was assess as high in 80%, moderately reduced--in 20% </plain></SENT>
<SENT sid="11" pm="."><plain>35% of the patients achieved clinico-laboratory remission </plain></SENT>
<SENT sid="12" pm="."><plain>The disease activity dropped to degree I-II in 65% of patients </plain></SENT>
<SENT sid="13" pm="."><plain>Structural changes in the joints stopped progressing in 77%, regress of the anatomic stage was seen in 20% of patients </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="2" ids="8378">Prednisolone</z:chebi> was discontinued in 7 and dose-reduced in 6 patients </plain></SENT>
<SENT sid="15" pm="."><plain>Exogenic <z:e sem="disease" ids="C0001622" disease_type="Disease or Syndrome" abbrv="">hypercorticism</z:e> relieved and growth resumed in <z:hpo ids='HP_0000001'>all</z:hpo> the patients </plain></SENT>
<SENT sid="16" pm="."><plain><z:chebi fb="0" ids="4031">Neoral</z:chebi> proved effective both in early and late SJRA, inhibited destruction both in patients in remission and in active disease </plain></SENT>
<SENT sid="17" pm="."><plain>Side effects were: <z:hpo ids='HP_0000998'>hypertrichosis</z:hpo> in 13 patients, moderate blood <z:hpo ids='HP_0000822'>hypertension</z:hpo> in 1 case </plain></SENT>
<SENT sid="18" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="4031">Neoral</z:chebi> can control the disease </plain></SENT>
<SENT sid="19" pm="."><plain>It is indicated both in early and late SJRA in the presence of aggressive course markers, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0263776" disease_type="Disease or Syndrome" abbrv="">coxitis</z:e> with <z:hpo ids='HP_0010885'>aseptic necrosis</z:hpo> of the head of the femur or free of it </plain></SENT>
<SENT sid="20" pm="."><plain><z:chebi fb="0" ids="4031">Neoral</z:chebi> treatment should be started as early as on the first year of the disease, before the structural changes in the joints </plain></SENT>
<SENT sid="21" pm="."><plain>For safe long-term therapy it is valid to give <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> in monotherapy or in combination with voltaren in minimal doses </plain></SENT>
<SENT sid="22" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroids</z:chebi> are used on demand </plain></SENT>
<SENT sid="23" pm="."><plain>The preference should be given to intraarticular or intravenous prolonged drugs but not oral <z:chebi fb="2" ids="8378">prednisolone</z:chebi> which may course such severe complications as <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, nanism </plain></SENT>
</text></document>